Category: 3. Business

  • Assessing Valuation After Recent Modest Gains Catch Investor Attention

    Assessing Valuation After Recent Modest Gains Catch Investor Attention

    Mattel (MAT) shares have shown modest gains over the past month, catching some attention from investors looking to understand recent movements. While the news front has been quiet, the steady performance warrants a closer look at underlying metrics.

    See our latest analysis for Mattel.

    Mattel’s recent momentum is hard to ignore, with a 7.5% share price return over the past month and an impressive 11.8% gain year-to-date. These moves build on a solid foundation, as the company has also delivered a 6.1% total shareholder return over the last year. This may signal that investor confidence could be gradually gaining traction.

    If you’re interested in finding stocks with similar upside or renewed momentum, now’s the perfect chance to broaden your investing universe and discover fast growing stocks with high insider ownership

    With shares trading about 20 percent below analyst targets and modest underlying growth, is Mattel overlooked by the market, or is optimism already reflected in its price? Is this a genuine buying opportunity, or is future growth already accounted for in the current price?

    Mattel is currently trading at a price-to-earnings (P/E) ratio of 14.3x, which reflects how investors value its earnings relative to the share price. At the last close of $19.83, this multiple suggests the stock is attractively priced, especially when compared to its fair value metrics.

    The P/E ratio is widely used for consumer durables companies because it helps investors assess how much they are paying for each dollar of earnings. For Mattel, being priced at 14.3x earnings indicates a market expectation of steady, but not exceptional, profit growth.

    This valuation appears even more appealing in context, as the industry average stands at 21.2x. This means Mattel is being valued at a significant discount to its global peers. Additionally, our estimated Fair Price-to-Earnings Ratio for Mattel is 15.3x, which is higher than where the shares are currently trading. If market sentiment were to shift toward the fair or industry multiple, the share price could move up meaningfully.

    Explore the SWS fair ratio for Mattel

    Result: Price-to-Earnings of 14.3x (UNDERVALUED)

    However, softer revenue growth or unexpected industry headwinds could quickly offset the current momentum and affect the stock’s valuation in the future.

    Find out about the key risks to this Mattel narrative.

    Looking at Mattel through the lens of our DCF model offers a sharper contrast. The SWS DCF model estimates a fair value of $46.10 per share, which is substantially higher than the current market price. This suggests the stock could be deeply undervalued if the growth assumptions hold up. Could this large gap signal greater upside, or are investors missing risks hidden in future projections?

    Look into how the SWS DCF model arrives at its fair value.

    MAT Discounted Cash Flow as at Nov 2025

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Mattel for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 926 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

    Whether you agree with this analysis or prefer drawing your own conclusions from the numbers, you can review the data and shape your own story in just a few minutes, or simply Do it your way

    A great starting point for your Mattel research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    Keep your portfolio on the cutting edge by tapping into curated ideas other investors overlook. You might just spot tomorrow’s winners before the crowd catches on.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include MAT.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Inside the Strange and Lonely Test Run of a New Cruise Ship – The Wall Street Journal

    1. Inside the Strange and Lonely Test Run of a New Cruise Ship  The Wall Street Journal
    2. Park West Gallery Celebrity Xcel  Travel And Tour World
    3. 11 countries added to methanol warning list – a year to the day since Simone White’s death  TTG Media
    4. Exclusive: Donna Kelce Shares Her Love of Cruising—and Her Next Family Trip  parade.com
    5. Inside the naming ceremony that launched Celebrity Xcel  Nonstop Local News Montana

    Continue Reading

  • Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma

    Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma

    Erdafitinib (Balversa) had a predictable toxicity profile and showed early efficacy signals in patients with recurrent or progressive IDH wild-type glioma with FGFR-TACC (F3T3) gene fusions, according to findings from the safety run-in cohort of the phase 2 ETCTN 10559 trial (NCT05859334), which were presented at the 2025 Society for Neuro-Oncology Annual Meeting.1 The agent also generated durable responses in this analysis.

    The safety run-in cohort completed therapy in October 2024, and 8 mg daily continuous dosing was identified as the recommended phase 2 dose (RP2D) of erdafitinib. One patient experienced a dose-limiting toxicity (DLT), which was grade 3 central serous retinopathy; this was the only grade 3 treatment-emergent adverse effect (TEAE) reported and was the only TEAE that led to erdafitinib discontinuation. Any TEAEs and grade 1 TEAEs were reported in all patients during the DLT period of cycle 1; no TEAEs were grade 4 or higher. Grade 2 TEAEs included dyspepsia (n = 2), hyperphosphatemia (n = 1), and hyponatremia (n = 1). Grade 1 hyperphosphatemia was common (n = 4). No TEAEs led to erdafitinib dose reductions or treatment interruptions. Notably, 1 patient experienced grade 3 cerebral edema that was deemed unrelated to treatment.

    Preliminary efficacy data were available for 5 patients. Best overall responses were complete response (CR; n = 1), partial response (PR; n = 2), stable disease (n = 1), and progressive disease (n = 1).

    Erdafitinib in F3T3 Fusion–Positive Glioma: Highlights

    • The safety profile of erdafitinib in patients with recurrent or progressive IDH wild-type glioma with F3T3 gene fusions was predictable and within expectations for the agent in other tumor types, leading to the selection of 8 mg daily continuous dosing as the RP2D.
    • Erdafitinib showed early efficacy signals and durable responses, with preliminary efficacy data for 5 patients showing best overall responses of CR (n = 1), PR (n = 2), SD (n = 1), and PD (n = 1).
    • The investigation of erdafitinib was based on the fact that F3T3 gene fusions are the most prevalent gene fusions in adult glioma and have demonstrated strong oncogenic activity and sensitivity to F3T3 inhibitors in prior studies.

    “The safety profile of erdafitinib within gliomas is within [the] expected known safety profile [of the agent] in other tumor types, and we were able to identify durable responses in this population,” lead study author Macarena de la Fuente, MD, stated in the presentation.

    de la Fuente is an associate professor of neuro-oncology, chief of the Neuro-Oncology Division, the clinical service leader for the Neuro-Oncology Service Line, chair of the Neuro-Oncology Site Disease Group, the director of the Neuro-Oncology Fellowship Program, and the leader of the Oncology Clinical Service for Neuro-Oncology at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center in Florida.

    What was the rationale for investigating erdafitinib in patients with glioma?

    F3T3 gene fusions are the most prevalent gene fusions in adult glioma and are present in approximately 3% to 6% of adult patients with IDH wild-type glioma. F3T3 fusions are truncal alterations that emerge during gliomagenesis and independently predict favorable outcomes in gliomas; these fusions are also retained in recurrent glioblastoma. In vitro and in vivo studies have shown that F3T3 fusions have strong oncogenic activity and sensitivity to F3T3 inhibitors.

    Erdafitinib, a potent, oral pan-FGFR TKI, was FDA approved in 2024 for the salvage treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alterations, as determined by an FDA-approved test, whose disease has progressed during or after treatment with 1 or more prior lines of systemic therapy.2 Responses to erdafitinib in patients with glioma have been reported in basket trials, but prior to the ETCTN 10559 study, no clinical trials focused solely on examining the activity of the agent in gliomas harboring F3T3 fusions.1

    What is the design of the ETCTN 10559 trial of erdafitinib in glioma?

    This multicenter, single-arm trial enrolled patients with recurrent or progressive F3T3 fusion–positive glioma. The trial was designed to have 2 safety lead-in cohorts. Cohort 1 (n = 6) evaluated the agent at a continuous dose of 8 mg daily. If at least 2 DLT events were observed, patients would be enrolled in the safety lead-in cohort 2 (n = 6) and receive erdafitinib at a continuous daily dose of 6 mg; if 1 or no DLT events were observed in either cohort, an additional 21 patients would be enrolled in the dose-expansion cohort. If at least 2 DLT events were observed at the 6-mg dose level, the trial would be stopped.

    The presently reported cohort determined the safety, tolerability, and RP2D of erdafitinib at the 8-mg dose in this population.

    Patients had a mean age of 63.3 years (standard deviation, 6.9) and a median age of 64 years (range, 52-72). Three patients each were male and female. Most patients were White (n = 5) and not Hispanic or Latino (n = 4). All patients had grade 4 glioblastoma and had received prior radiation and prior temozolomide. Most patients had a Karnofsky performance score of 90 (n = 5), and 2 patients each had received 1, 2, and 3 prior lines of therapy.

    What do case studies show about the efficacy of erdafitinib in glioblastoma?

    de la Fuente highlighted results from 2 case studies from the safety run-in cohort. One patient was a 60-year-old woman with recurrent World Health Organization (WHO) grade 4 F3T3 fusion–positive glioblastoma. This patient underwent biopsy, then received radiotherapy plus temozolomide, followed by 6 cycles of adjuvant temozolomide. At 15 months from her initial diagnosis, this patient presented with clinical and radiographic disease. She enrolled in ETCTN 10559 in April 2024 and completed over 19 cycles of therapy. Treatment is ongoing in this patient, who achieved a PR at cycle 1 and a CR at cycle 13.

    The second case study involved a 68-year-old man with IDH wild-type, F3T3 fusion–positive, WHO grade 4 glioblastoma that was MGMT promoter unmethylated. This patient underwent subtotal resection of a right parieto-temporal mass, then received 3 weeks of hypofractionated radiotherapy with concurrent temozolomide, followed by 4 cycles of adjuvant temozolomide. He enrolled in ETCTN 10559 in October 2024 and achieved a PR at cycle 8.

    What are the next steps for investigating erdafitinib in patients with glioma?

    The dose-expansion cohort of this phase 2 trial began enrollment in February 2025. In total, 90% of the planned 21 patients have been enrolled, and 12 clinical trial sites have been activated.

    References

    1. de la Fuente M, Bhatia A, A phase 2 study of erdafitinib in patients with recurrent or progressive IDH-wild type glioma with FGFR-TACC gene fusions: safety run-in cohort results. Presented at: 2025 SNO Annual Meeting; November 19-23, 2025; Honolulu, Hawaii. Abstract CTNI-61.
    2. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma. FDA. January 19, 2024. Accessed November 22, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma

    Continue Reading

  • How Analysts See the Evolving Story for Chedraui After Recent Price Target Cuts

    How Analysts See the Evolving Story for Chedraui After Recent Price Target Cuts

    Grupo Comercial Chedraui has seen its consensus analyst price target decrease modestly from MX$160.57 to MX$159.86. This shift follows a period of increased uncertainty and slightly higher discount rates. These changes reflect analysts’ evolving views of the company’s near-term prospects. Stay tuned to discover how you can monitor future updates as Chedraui’s narrative continues to develop in a changing retail landscape.

    Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Grupo Comercial Chedraui. de.

    Analysts continue to assess Grupo Comercial Chedraui’s outlook amidst changing market conditions. Below are the key takeaways from recent analyst commentary, reflecting both bullish and bearish perspectives on the stock’s prospects.

    🐂 Bullish Takeaways

    • While the broader tone has grown more cautious, some analysts maintain that Grupo Comercial Chedraui has demonstrated strengths in operational execution and cost control. These factors have supported previous neutral stances.

    • Key drivers often credited by bullish or neutral analysts include stable growth momentum and transparency in corporate reporting. However, specific recent upgrades or price target increases have not been reported in the latest coverage.

    🐻 Bearish Takeaways

    • Grupo Santander recently downgraded Chedraui from Neutral to Underperform and set a new price target of MXN 157.

    • This downgrade highlights concerns around valuation, as some analysts believe that much of the potential upside is already reflected in the current share price.

    • A heightened focus on near-term risks and market uncertainties also contributed to the more negative outlook from Grupo Santander.

    Taken together, these perspectives highlight the market’s ongoing debate regarding Chedraui’s valuation and execution quality. Some analysts remain cautious about near-term risks despite longer-term strengths in growth and operational management.

    Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

    BMV:CHDRAUI B Earnings & Revenue History as at Nov 2025
    • The consensus analyst price target has decreased modestly from MX$160.57 to MX$159.86.

    • The discount rate has risen slightly, moving from 15.12% to 15.16%.

    • Revenue growth expectations have been reduced from 8.54% to 7.72%.

    • Net profit margin projections have fallen from 3.24% to 2.79%.

    • The future P/E multiple has increased significantly from 18.91x to 22.47x.

    Continue Reading

  • Why The Narrative Around ITV Is Shifting Amidst Media Sale Talks and Analyst Revisions

    Why The Narrative Around ITV Is Shifting Amidst Media Sale Talks and Analyst Revisions

    ITV’s stock narrative has shifted recently, as the company’s price target remains steady at £0.80 per share while several key assumptions have adjusted. A slightly lower discount rate and slower revenue growth reflect both persistent caution and underlying confidence among analysts. Read on to see what is driving these changes and how you can stay informed as ITV’s story continues to unfold.

    Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value ITV.

    🐂 Bullish Takeaways

    • JPMorgan maintained its Overweight rating on ITV shares, indicating continued confidence in the company’s longer-term value proposition.

    • Analysts highlight ITV’s ability to navigate market conditions, pointing out its steady execution and efforts to maintain operational transparency.

    🐻 Bearish Takeaways

    • JPMorgan lowered its price target for ITV to 105 GBp from 112 GBp. This reflects some reservations around near-term growth prospects and challenges ahead.

    • Concerns persist that ITV’s current valuation may already reflect much of the anticipated upside. Ongoing market caution continues to influence target adjustments.

    Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

    LSE:ITV Community Fair Values as at Nov 2025
    • Comcast is reportedly in discussions to acquire ITV’s media and entertainment division, which could lead to significant changes within the UK’s broadcasting landscape.

    • ITV has confirmed that it is engaged in early-stage talks with Sky Limited for a possible sale of its media and entertainment business, with a reported enterprise value of £1.6 billion. No agreement has been finalized.

    • If a sale proceeds, it would include ITV’s terrestrial channels and streaming service ITVX, while ITV Studios, the production arm, would remain under ITV’s ownership.

    • Negotiations are ongoing with several interested parties, including Comcast, but there is no certainty that any deal will ultimately be reached.

    • Fair Value remains unchanged at £0.80 per share.

    • The Discount Rate has decreased slightly from 7.25% to 7.15%.

    • Revenue Growth has fallen modestly from 2.69% to 2.63%.

    • Net Profit Margin has edged down from 6.27% to 6.15%.

    • The future P/E ratio has risen slightly from 15.76x to 16.06x.

    A Narrative is a simple, powerful tool that lets investors connect the story behind a company to the numbers, such as future revenue, earnings, and fair value. Available on Simply Wall St’s Community page, Narratives make it easy to see how a company’s outlook changes with new news or results. By tracking Fair Value versus Price, investors can decide when to buy or sell while updates flow in dynamically.

    Ready for the full story? Read the original ITV Narrative to see why investors are following along for:

    • Real-time updates as ITV’s digital transformation and media sale talks reshape market expectations

    • Insights into how cost controls, global content growth, and digital partnerships impact future earnings and margins

    • Key risks from advertising shifts, increased competition, and regulatory changes, plus how these affect ITV’s valuation and your next decision

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ITV.L.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Evaluating Valuation Following a 69% Three-Month Share Price Surge

    Evaluating Valuation Following a 69% Three-Month Share Price Surge

    Victoria’s Secret (VSCO) has caught the attention of investors following recent moves in its stock price. The past month has delivered a gain of 11%, while the past three months show a 69% jump. This reflects strong market interest.

    See our latest analysis for Victoria’s Secret.

    Victoria’s Secret has surged into the spotlight with momentum building over the past quarter. While the 90-day share price return stands out at nearly 69%, the stock still posts a negative total shareholder return of just over 1% in the past year. That recent burst of optimism suggests investors may be betting on a turnaround or re-rating of the brand as sentiment shifts from last year’s sluggish run.

    If you’re watching this strong move and keen to see what else is unfolding across the market, now is a great time to broaden your search with fast growing stocks with high insider ownership

    But with shares now well above most analyst targets and only a modest lift in annual revenue, the key question is whether Victoria’s Secret is now trading at a bargain or if the market has already factored in stronger future growth.

    Compared to Victoria’s Secret’s last close price, the most widely followed narrative places fair value much lower, signaling the recent rally has pushed shares well above what consensus numbers support. The narrative sets a clear calculation for why this is the case.

    The analysts have a consensus price target of $22.7 for Victoria’s Secret based on their expectations of its future earnings growth, profit margins, and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $27.0, and the most bearish reporting a price target of just $17.0.

    Read the complete narrative.

    Could a slowdown in earnings and a high projected profit multiple really justify the gap between narrative value and market price? The assumptions driving this calculation center on how the company will balance modest revenue growth with tighter margins in the coming years. See what’s behind the numbers.

    Result: Fair Value of $22.7 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent tariff pressures and ongoing declines in mall traffic could still threaten Victoria’s Secret’s ability to sustain recent gains and margin improvements.

    Find out about the key risks to this Victoria’s Secret narrative.

    Our SWS DCF model puts Victoria’s Secret’s fair value at $48.49, which is well above the current share price. This suggests shares could be undervalued if the underlying cash flow assumptions play out. The key question is whether these longer-term projections can offset concerns about slower earnings growth.

    Look into how the SWS DCF model arrives at its fair value.

    VSCO Discounted Cash Flow as at Nov 2025

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Victoria’s Secret for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 925 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

    If you want to test these numbers for yourself or craft your own perspective, building a personal narrative takes just a few minutes. Do it your way

    A great starting point for your Victoria’s Secret research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

    Don’t settle for one idea when there’s a world of growth stocks and fresh trends waiting for you. Use the Simply Wall Street Screener to uncover unique opportunities that could boost your portfolio’s potential.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include VSCO.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • AI Investors Want More Making It and Less Faking It – The Wall Street Journal

    1. AI Investors Want More Making It and Less Faking It  The Wall Street Journal
    2. The world’s biggest company just told everyone to chill out  CNN
    3. Hyperliquid News Today: Doubts from Investors Cause Sharp Drop in AI Shares as Profits Fall Short of Justifying High Valuations  Bitget
    4. Friday charts: Elements of a bubble  Blockworks
    5. Uneasy Acceleration  The Statesman

    Continue Reading

  • Global banks pour into India as regulators open up to foreign money

    Global banks pour into India as regulators open up to foreign money

    Stay informed with free updates

    Global banks are buying up stakes in Indian lenders as the country’s government and regulators become increasingly relaxed about foreign entities acquiring significant holdings.

    Since the start of the year, India’s financial sector has had $8bn worth of deals from foreign companies, up from $2.3bn last year and $1.4bn in 2023, according to Dealogic data.

    The transactions reflected growing investor confidence in India’s economy and had “opened up a new chapter” in Indian banking, said analysts at Mumbai-based Motilal Oswal Financial Services in a note.

    They come as officials have laid out ambitions to consolidate the sector, with finance minister Nirmala Sitharaman this month saying the government wanted to create more “big banks”.

    The central bank has said it is reviewing whether to relax a 15 per cent shareholding cap by any single foreign investor in a non-government-owned lender, although it has already been approving large sales on a case-by-case basis.

    The sector’s biggest cross-border deal this year was the $3bn acquisition of a 60 per cent stake in mid-sized bank RBL by Dubai’s largest lender, Emirates NBD. Japan’s Sumitomo Mitsui Financial Group bought a 24.2 per cent stake in Yes Bank for about $1.7bn, becoming its biggest shareholder.

    Mitsubishi UFJ Financial Group, Japan’s largest lender by assets, is in advanced talks with multiple non-banking financial groups for the purchase of a large stake, according to people familiar with the matter.

    Although there have been reports of negotiations between MUFG and Chennai-based Shriram Finance for a 20 per cent stake worth $2.6bn, the people said the deal was yet to be finalised and MUFG was still exploring other options. “The situation is still fluid,” said one of the people.

    MUFG declined to comment. Shriram said it was “not aware of any developments on this front”.

    Foreign banks are casting a keener eye on India’s financial groups because of the country’s robust economic growth, according to Yatin Singh, chief executive of investment banking at Emkay Global Financial Services in Mumbai. He noted that likely targets included a handful of public sector banks that the government would like to privatise.

    “For mature economies like Japan, which now have an ageing population and have capital, they need to find a way to deploy that capital in a way where the risk-adjusted return makes sense,” he said. “India is in that way an attractive option.”

    Some content could not load. Check your internet connection or browser settings.

    Vikram Raghani, senior partner at JSA, an Indian law firm that has been involved in recent banking deals, said previous mergers and acquisitions might have involved lenders that were “in some kind of stress”.

    “Now the mindset of the regulator and the government appears to be changing to allow banks to tap into global capital for growth and expansion,” he said. “If our banks have to go to the next level, they will need capital and international expertise.”

    A person familiar with the Reserve Bank of India’s thinking said it was coming around to more foreign participation, calling the recent spate of deals a “vote of confidence” in India’s economy and banking sector.

    The person added that overseas investors were targeting mid-sized banks that were easier to acquire and had more room to grow.

    A partner at one of India’s leading venture capital firms said shadow banks were also garnering interest after the RBI eased restrictions put in place in 2023 in response to a post-pandemic credit binge that left many households in debt.

    Since the industry’s recovery, the RBI has been telling shadow banks “you can go ahead and expand your books and grow faster”, the partner said.

    One of the biggest deals this year involved Indian shadow bank Sammaan Capital, in which International Holding Company, the Middle East’s second-largest company by market value, purchased a controlling 43.5 per cent stake for $1bn.

    India Business Briefing

    The Indian professional’s must-read on business and policy in the world’s fastest-growing big economy. Sign up for the newsletter here

    Kunal Shroff, managing partner at private equity firm ChrysCapital, said valuations in India’s financial services sector looked attractive compared with the rest of the country’s market.

    Indian equities trade at 23 times 12-month forward earnings, making it the world’s most expensive emerging market, while the country’s financial companies trade at 17 times, according to Goldman Sachs analysts.

    “There’s enough credit demand,” said Singh at Emkay. “Whichever [lending] segment you pick up, you’d find a very, very large opportunity over the next 15, 20, 25 years. Anyone who’s buying a bank in India is taking, I’m sure, a 50-year view.”

    Continue Reading

  • Investors in Fraser & Neave Holdings Bhd (KLSE:F&N) have seen favorable returns of 68% over the past three years

    Investors in Fraser & Neave Holdings Bhd (KLSE:F&N) have seen favorable returns of 68% over the past three years

    One simple way to benefit from the stock market is to buy an index fund. But if you choose individual stocks with prowess, you can make superior returns. For example, the Fraser & Neave Holdings Bhd (KLSE:F&N) share price is up 55% in the last three years, clearly besting the market return of around 11% (not including dividends). However, more recent returns haven’t been as impressive as that, with the stock returning just 18% in the last year, including dividends.

    Let’s take a look at the underlying fundamentals over the longer term, and see if they’ve been consistent with shareholders returns.

    AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

    While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

    During three years of share price growth, Fraser & Neave Holdings Bhd achieved compound earnings per share growth of 9.9% per year. This EPS growth is lower than the 16% average annual increase in the share price. This suggests that, as the business progressed over the last few years, it gained the confidence of market participants. It is quite common to see investors become enamoured with a business, after a few years of solid progress.

    The company’s earnings per share (over time) is depicted in the image below (click to see the exact numbers).

    KLSE:F&N Earnings Per Share Growth November 23rd 2025

    This free interactive report on Fraser & Neave Holdings Bhd’s earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

    As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It’s fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Fraser & Neave Holdings Bhd’s TSR for the last 3 years was 68%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

    We’re pleased to report that Fraser & Neave Holdings Bhd shareholders have received a total shareholder return of 18% over one year. And that does include the dividend. That gain is better than the annual TSR over five years, which is 3%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. It’s always interesting to track share price performance over the longer term. But to understand Fraser & Neave Holdings Bhd better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we’ve spotted 1 warning sign for Fraser & Neave Holdings Bhd you should know about.

    Of course Fraser & Neave Holdings Bhd may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

    Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Continue Reading

  • Walmart makes African debut with South African store launch

    Walmart makes African debut with South African store launch

    JOHANNESBURG, Nov 22 (Reuters) – Walmart (WMT.N), opens new tab opened its first store in South Africa on Saturday, marking the U.S. retail giant’s debut on the African continent as it seeks a stake in a competitive market.

    More than a hundred shoppers queued for hours outside the store to take advantage of Walmart’s “Everyday Low Prices” and shop international products that are not easily available in South Africa such as designer counter-top air fryers by Drew Barrymore, Labubu dolls and Dr.Pepper sodas.

    Sign up here.

    “I’m actually here for a specific product that you can’t really get in South Africa….it’s a children’s toy, Labubu,” Refilwe Mabale, told Reuters.

    Some, like Tshepo Rambau, were hoping to snap up deals during Black Friday weekend. The 44-year-old told Reuters while standing in the queue that he was eyeing tech products like WIFI extenders.

    “Hopefully I’ll get them cheaper here,” he said.

    The retailer will also be offering a sixty-minute online delivery service. This places it in direct competition with Checkers’ Sixty60 on-demand delivery service owned by South Africa’s largest grocery retailer Shoprite (SHPJ.J), opens new tab.

    “Opening the first Walmart store in South Africa is about much more than a business milestone, it is a commitment to helping customers save money and live better by consistently delivering the lowest total cost for the basket of products they need,” Andrea Albright, executive vice president of Walmart, said in a statement.

    The store, located in Roodepoort, west of Johannesburg, has has created 80 new jobs and has collaborated with 15 local small- and medium-enterprises, the retailer said.

    Reporting by Siyanda Mthethwa, Editing by William Maclean

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading